10x Genomics

Biotechnology tools for genomic research

Pleasanton, California, United States

About 10x Genomics

10x Genomics develops products that enhance genomic research, particularly in the life sciences sector. Their main offerings include tools for single-cell analysis, spatial gene expression, and immune profiling, which allow researchers to examine genetic information in great detail. These products help scientists understand complex biological systems and are essential for advancing personalized medicine and research capabilities. 10x Genomics sells laboratory equipment, consumables like reagents and microfluidic chips, and software solutions for data analysis. Their focus on high-quality products and support distinguishes them from competitors, making them a leader in the specialized field of genomic research.

Pleasanton, CaliforniaHeadquarters
2012Year Founded
$214.9MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
1,001-5,000Employees

Benefits

Comprehensive health benefits
Generous time off
Parental leave

Risks

Increased competition in single-cell analysis could impact 10x Genomics' market share.
Patent litigation with Bruker Corporation poses legal and financial risks.
Reliance on limited suppliers risks supply chain disruptions affecting production timelines.

Differentiation

10x Genomics offers unique single-cell and spatial analysis tools for detailed genomic research.
Their On-Chip Multiplex solution reduces handling time, enhancing laboratory efficiency.
The company provides cost-effective genomic solutions, democratizing access to single-cell analysis.

Upsides

Growing demand for personalized medicine boosts need for 10x Genomics' high-resolution data tools.
AI integration in genomics enhances data analysis, benefiting 10x Genomics' software offerings.
Expansion of CRISPR applications increases demand for precise genomic analysis tools.

Funding

Total raised$214.88 M
Latest valuation$3.70 B
StageIPO
IPO
8/31/2019
$390
$3.70 B
$35
$1.30 B
DEBT
3/31/2018
$75
$56
$277.50 M
SERIES A
10/31/2013
$22
$112.00 M